CALC supply chain intelligence for CalciMedica, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
CalciMedica, Inc. (CALC) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CONTRACT-DEVELOPMENT-AND-MANUFACTURING-ORGANIZAT | CONTRACT-DEVELOPMENT-AND-MANUFACTURING-ORGANIZAT | 90% | The Company has historically entered into contracts in the normal course of business with contract development and manufacturing organizations, for the manufacturing process development and the precl… |
| VENDORS | VENDORS | 90% | The Company has historically entered into contracts in the normal course of business with contract development and manufacturing organizations, for the manufacturing process development and the precl… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| MYGN | Myriad Genetics, Inc. | 72% | vernmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide heal… |
| MYGN | Myriad Genetics, Inc. | 72% | Reciprocal relationship from MYGN graph: Reciprocal relationship from CALC graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from CALC graph: Reciprocal relationship from MYGN g… |
| SNYNF | Sanofi | 72% | vernmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide heal… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from CALC graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from CALC graph: vernmental bodies to limit the sc… |
| CALCIMEDICA-SUBSIDIARY-INC | CALCIMEDICA-SUBSIDIARY-INC | 62% | 2023, Graybug Vision, Inc. (“Graybug”) completed a reverse merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of November … |
| CALM | Cal-Maine Foods, Inc. | 62% | Reciprocal relationship from CALM graph: Reciprocal relationship from CALC graph: 2023, Graybug Vision, Inc. (“Graybug”) completed a reverse merger transaction in accordance with the terms and condit… |
| GRAYBUG-VISION-INC | GRAYBUG-VISION-INC | 62% | 2023, Graybug Vision, Inc. (“Graybug”) completed a reverse merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of November … |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| CALC-DEBT | Debt stack $6.7M | 90% | Market cache reports total debt of $6.7M. |
| CALC-DEBT-3733 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| CALC-DEBT-3732 | Warrants outstanding: 216000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| CALC-OWNER-SHEETS-SMITH-INVESTMENT-MANAGEMENT | Sheets Smith Investment Management | 95% | 13F/ownership overlay lists Sheets Smith Investment Management; shares held 51,100; ownership 0.90%; value $31,865; as of 2025-09-30. |
| CALC-OWNER-AISLING-CAPITAL-MANAGEMENT-LP | Aisling Capital Management LP | 95% | 13F/ownership overlay lists Aisling Capital Management LP; shares held 521,114; ownership 9.20%; value $324,966; as of 2025-09-30. |
| CALC-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 407,801; ownership 7.20%; value $254,304; as of 2025-12-31. |
| CALC-OWNER-RENAISSANCE-TECHNOLOGIES-LLC | Renaissance Technologies, LLC | 95% | 13F/ownership overlay lists Renaissance Technologies, LLC; shares held 70,000; ownership 1.24%; value $43,652; as of 2025-09-30. |
| CALC-OWNER-MERITAGE-PORTFOLIO-MANAGEMENT | Meritage Portfolio Management | 95% | 13F/ownership overlay lists Meritage Portfolio Management; shares held 61,539; ownership 1.09%; value $38,375; as of 2025-12-31. |
| CALC-OWNER-STONEHAGE-FLEMING-FINANCIAL-SERVICES-HOL | Stonehage Fleming Financial Services Holdings Limited | 95% | 13F/ownership overlay lists Stonehage Fleming Financial Services Holdings Limited; shares held 53,703; ownership 0.95%; value $33,489; as of 2025-12-31. |
| CALC-OWNER-ENVESTNET-ASSET-MANAGEMENT-INC | Envestnet Asset Management Inc. | 95% | 13F/ownership overlay lists Envestnet Asset Management Inc.; shares held 76,705; ownership 1.35%; value $47,833; as of 2025-09-30. |
| CALC-OWNER-SOLEUS-CAPITAL-MANAGEMENT-L-P | Soleus Capital Management, L.P. | 95% | 13F/ownership overlay lists Soleus Capital Management, L.P.; shares held 683,904; ownership 12.08%; value $426,482; as of 2025-09-30. |
| CALC-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 98,852; ownership 1.75%; value $61,644; as of 2025-09-30. |
| CALC-OWNER-DEERFIELD-MANAGEMENT-COMPANY-L-P | Deerfield Management Company, L.P | 95% | 13F/ownership overlay lists Deerfield Management Company, L.P; shares held 1,300,000; ownership 22.96%; value $810,680; as of 2025-09-30. |
| CALC-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 30 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ALLO | Allogene Therapeutics, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| BNTC | Benitec Biopharma Inc. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CALM | Cal-Maine Foods, Inc. | 100.00 | 1 | ['customer'] |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 100.00 | 2 |